Background: Potent P2Y12 blockers are preferred in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI). However, the risk of bleeding remains a major concern. We assessed the association of potent P2Y12 blockers with ischemic and bleeding outcomes in patients with NSTEMI.
Methods: From the Korea Acute Myocardial Infarction Registry-National Institute of Health database, 4927 patients with NSTEMI receiving drug-eluting stents (DES) were divided into potent P2Y12 blocker (ticagrelor or prasugrel, n=901) and clopidogrel (n=3180) groups. Propensity-matched 12-month ischemic and bleeding events were compared. Patients who received anticoagulants or who discontinued P2Y12 blockers or switched between potent P2Y12 blockers and clopidogrel were excluded.
Results: In the overall population, patients at higher ischemic and bleeding risks more often received clopidogrel. After propensity matching (n=901 in each group), 12-month rates of major adverse cardiac and cerebrovascular events were lower (7.3% vs. 10.1%, p=0.038), but Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding rates were higher (5.9% vs. 2.2%, p<0.001) with potent P2Y12 blockers. Twelve-month rates of death from any cause, MI, stroke, or TIMI major bleeding were not different. On multivariate analysis, 12-month risk of TIMI major or minor bleeding was higher with B2 or C lesion, potent P2Y12 blocker use, body weight <60kg, and lower with time to PCI <12h and radial artery access.
Conclusions: In patients with NSTEMI receiving DES, potent P2Y12 blockers were associated with reduced ischemic but increased bleeding risk with similar net clinical benefits.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jjcc.2018.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel acridone derivatives as potential P2Y receptor inhibitors: integrating computational modeling and experimental analysis.
J Biomol Struct Dyn
January 2025
Pharmacological and Diagnostic Research Center (PDRC), Al-Ahliyya Amman University, Amman, Jordan.
The combination of clopidogrel and acetylsalicylic acid is the standard treatment for atherosclerotic cardiovascular disease. Nonetheless, there is a pressing need for more potent P2Y receptor inhibitors with quicker onset, especially for early intervention in acute myocardial infarction. Integrating computational modeling, i.
View Article and Find Full Text PDFSTEMI Antithrombotic Therapy: The Evolving Role of P2Y12 Inhibitor Pretreatment in Contemporary Practice.
Rev Cardiovasc Med
November 2024
Cardiology Unit, Sant'Andrea University Hospital, 00189 Rome, Italy.
Article Synopsis
- The P2Y12 receptor is crucial for platelet activation and has been a focus of research, particularly in the context of treating acute coronary syndromes (ACS) with dual therapy of aspirin and clopidogrel, as shown in the landmark CURE trial from 2001.
- Advances in interventional cardiology, including drug-eluting stents and new P2Y12 inhibitors like ticagrelor and prasugrel, have significantly changed ACS treatment but challenges still exist, particularly with ST-elevation myocardial infarction (STEMI).
- The review highlights the efficacy and safety of using P2Y12 receptor antagonists as a pretreatment strategy for STEMI, stressing the need for personalized treatment plans and the future
The Comparative Effectiveness of Potent P2Y12 Inhibitors Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing PCI: National Registry Data.
J Clin Med
October 2024
Heart Institute, Medical School, University of Pécs, 7622 Pécs, Hungary.
Dual antiplatelet therapy (DAPT), which is essential in AMI management, combines aspirin with a P2Y12 receptor antagonist. This study compared the effectiveness of potent P2Y12 inhibitors versus clopidogrel in AMI patients treated with percutaneous coronary intervention (PCI). 65,986 AMI patients included in a nationwide prospective registry who underwent PCI and received DAPT were studied.
View Article and Find Full Text PDFBreaking boundaries: Ticagrelor monotherapy in high-risk patients.
Int J Cardiol Heart Vasc
December 2024
Medical Affairs, AstraZeneca Pharma India Ltd, India.
Atherosclerotic plaque formation is a leading cause of arterial thrombosis that significantly impacts global health by instigating major adverse cardiovascular events (MACE) like myocardial infarction (MI) and stroke. Platelets are central to this process, leading to the development of antiplatelet therapies, to mitigate MACE risks. The combination of aspirin with a potent P2Y inhibitor known as dual antiplatelet therapy (DAPT) is the standard for post-percutaneous coronary intervention (PCI) aimed at reducing ischemic events.
View Article and Find Full Text PDFSwitching from cangrelor to oral P2Y inhibitors: a focused review on drug-drug interactions.
Expert Opin Drug Metab Toxicol
January 2025
Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
Article Synopsis
- Cangrelor is an intravenous medication that inhibits platelet P2Y receptors, effectively preventing blood clots during procedures like coronary interventions, especially in patients not on oral P2Y inhibitors.
- Its rapid platelet inhibition raises concerns about potential drug-drug interactions (DDIs) when switching to oral P2Y inhibitors, which is critical for patient safety.
- Proper timing during the transition to oral P2Y inhibitors, particularly clopidogrel and prasugrel, is crucial to minimize DDI risks, and following existing guidelines can enhance treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!